# RudaCure Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rudacure-co

- Industry: Biotechnology
- Headquarters: Incheon, South Korea
- Website: www.rudacure.com
- Total disclosed funding: $5.1M
- Latest round: Series A (May 30, 2023)
- Investors on record: 4

## About

Based in Incheon, South Korea, and founded in 2018 by its CEO Yong-ho Kim, RudaCure Co., Ltd is a biotechnology company that develops a treatment for dry eye syndrome and treatment for chronic pain. In May 2023, RudaCure Co., Ltd raised an undisclosed amount of series A funding from Darae Strategy & Business.

Rudacure Co., Ltd develops ophthalmic diseases such as dry eye syndrome and age-related macular degeneration as well as provides treatment for neuropathic pain and cancer pain. It offers RCI001 for dry eye treatment, RCI002 for pain treatment, and RCI005 for macular degeneration treatment. In addition, the company also provides animal model development for pain and ophthalmic disease, electrophysiological research, and drug toxicity and evaluation services.

## Funding rounds

- Series A, May 30, 2023 — Darae Strategy & Business
- Series A, May 20, 2022, $4.7M — CKD Venture Capital, Y&ARCHER, Hanlim Pharm. Co., Ltd.
- Series A, Sep 16, 2021, $0.4M — Y&ARCHER

## Investors

- Y&ARCHER (https://capitalatlas.ai/funds/y-archer) — Series A
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series A
- Hanlim Pharm. Co., Ltd. — Series A
- Darae Strategy & Business (https://capitalatlas.ai/funds/darae-strategy-business) — Series A